- Nano cap Pulmatrix (NASDAQ:PULM +5.1%) is up on almost triple normal volume in response to results from a Phase 1 clinical trial assessing lead candidate PUR0200 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
- PUR0200 achieved a similar therapeutic effect to Boehringer Ingelheim's Spiriva HandiHaler (tiotropium bromide) Inhalation Spray at an 83% lower dose with more than 30% less plasma drug exposure.
- The value proposition of PUR0200, an improved inhaled tiotropium bromide, is enhanced efficacy by virtue of its iSPERSE dry powder technology which travels more easily into the lungs.
- The company is co-developing PUR0200 with Vectura Group plc (OTCPK:VEGPF) for the U.S. market.
- Previously: Pulmatrix teams up with Vectura to develop COPD candidate PUR0200; shares down 3% (Sept. 6, 2017)